Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder

Neural Plasticity

Volumn 11, Issue 1-2, 2004, Pages 133-149

  Viggiano, D ^a   Ruocco, L A ^a   Arcieri, S ^a   Sadile, Adolfo G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ADHD; Attention; Behavior; Dopamine system; Motor activity; Norepinephrine system; Norepinephrine transporter inhibitors; Prefrontal cortex; Review

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMPHETAMINE; ATOMOXETINE; DOPAMINE; GUANFACINE; METHYLPHENIDATE; NORADRENALIN; NORADRENALIN TRANSPORTER; REBOXETINE;

ADRENERGIC RECEPTOR BLOCKING; ADRENERGIC STIMULATION; ADRENERGIC TRANSMISSION; ANIMAL MODEL; ATTENTION DEFICIT DISORDER; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; EXCITABILITY; HUMAN; KNOCKOUT GENE; LOCOMOTION; NEGATIVE FEEDBACK; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROANATOMY; NEUROMODULATION; NONHUMAN; NORADRENERGIC SYSTEM; PREFRONTAL CORTEX; RAT; RETROSPECTIVE STUDY; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 4143071675     PISSN: 20905904     EISSN: None     Source Type: Journal    
DOI: 10.1155/NP.2004.133     Document Type: Review

References (124)

1. American Psychiatric Association, Task Force on DSM-IV. 2004. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). Washington DC, USA: APA.
2. Aoki C, Venkatesan C, Go CG, Forman R, Kurose H. 1998. Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immuno-cytochemical localization of noradrenergic receptors and axons. Cereb Cortex 8: 269-277.
3. Arnsten AF. 1997. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11: 151-162.
4. Aston-Jones G, Bloom FE. 1981. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci 1: 876-886.
5. Auclair A, Cotecchia S, Glowinski J, Tassin JP. 2002. D-amphetarnine fails to increase extracellular dopamine levels in mice lacking alpha 1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. J Neurosci 22: 9150-9154.
6. Barbelivien A, Ruotsalainen S, Sirvio J. 2001. Metabolic alterations in the prefrontal and cingulate cortices are related to behavioral deficits in a rodent model of attention-deficit hyperactivity disorder. Cereb Cortex 11: 1056-1063.
7. Barkley RA. 1977. A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18: 137-165.
8. Battaglia G, Fornai F, Busceti CL, Lembo G, Nicoletti F, De Blasi A. 2003. Alpha-1B adrenergic receptor knockout mice are protected against methamphetamine toxicity. J Neurochem 86: 413-421.
9. Berridge CW, Waterhouse BD. 2003. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 42: 33-84.
10. Biederman J, Spencer T. 1999. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46: 1234-1242.
11. Bjorklund A, Lindvall O. 1984. Dopamine containing systems in the CNS. In: Bjorklund A, Hokfelt T, eds, Handbook of Chemical Neuroanatomy. Amsterdam, the Netherlands: Elsevier; 55-122.
12. Bouret S, Sara SJ. 2002. Locus coeruleus activation modulates firing rate and temporal organization of odour-induced single-cell responses in rat piriform cortex. Eur J Neurosci 16: 2371-2382.
13. Brown VJ, Bowman EM. 2002. Rodent models of prefrontal cortical function. Trends Neurosci 25: 340-343.
14. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, et al. 2002. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27: 699-711.
15. Carboni E, Silvagni A, Valentini V, Di Chiara G. 2003. Effect of amphetamine, cocaine and depolarization by high potassium on extracellular dopamine in the nucleus accumbens shell of SHR rats. An in vivo microdyalisis study. Neurosci Biobehav Rev 27: 653-659.
16. Carboni E, Tanda GL, Frau R, Di Chiara G. 1990. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the pre-frontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55: 1067-1070.
17. Carli M, Robbins TW, Evenden JL, Everitt BJ. 1983. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav Brain Res 9: 361-380.
18. Carson RP, Robertson D. 2002. Genetic manipulation of noradrenergic neurons. J Pharmacol Exp Ther 301: 410-417.
19. Cases O, Lebrand C, Giros B, Vitalis T, De Maeyer E, Caron MG, et al. 1998. Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs. J Neurosci 18: 6914-6927.
20. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP, et al. 1996. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53: 607-616.
21. Castellanos FX, Tannock R. 2002. Neuroscience of Attention-Deficit/Hyperactivity Disorder: the search for endophenotypes. Nature Reviews 3: 617-628.
22. Cerbone A, Sadile AG. 1994. Behavioral habituation to spatial novelty: interference and noninterference studies. Neurosci Biobehav Rev 18: 497-518.
23. Chudasama Y, Passetti F, Rhodes SE, Lopian D, Desai A, Robbins TW. 2003. Dissociable aspects of performance on the 5-choice serial reaction time task following lesions of the dorsal anterior cingulate, infralimbic and orbitofrontal cortex in the rat: differential effects on selectivity, impulsivity and compulsivity. Behav Brain Res 146: 105-119.
24. Conti LH, Youngblood KL, Printz MP, Foote SL. 1997. Locus coeruleus electrophysiological activity and responsivity to corticotropin-releasing factor in inbred hypertensive and normotensive rats. Brain Res 774: 27-34.
25. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA. 2001. Use of dopamine-beta-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 298: 651-657.
26. Dahlstrom A, Fuxe K. 1964. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in cell bodies of brain stem neurons. Acta Physiol Scand 62 Suppl 232: 1-55.
27. Dalen L, Sonuga-Barke EJ, Hall M, Remington B. 2004. Inhibitory deficits, delay aversion and preschool AD/HD. implications for the dual pathway model. Neural Plast 11: 1-12.
28. Darracq L, Blanc G, Glowinski J, Tassin JP. 1998. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J Neurosci 18: 2729-2739.
29. Davies MF, Tsui JY, Flannery JA, Li X, DeLorey TM, Hoffman BB. 2003. Augmentation of the noradrenergic system in alpha-2 adrenergic receptor deficient mice: anatomical changes associated with enhanced fear memory. Brain Res 986: 157-165.
30. Deacon RM, Penny C, Rawlins JN. 2003. Effects of medial prefrontal cortex cytotoxic lesions in mice. Behav Brain Res 139: 139-155.
31. Deutch AY, Goldstein M, Roth RH. 1986. Activation of the locus coeruleus induced by selective stimulation of the ventral tegmental area. Brain Res 363: 307-314.
32. Dev BR, Philip L. 1996. Extracellular catechol and indole turnover in the nucleus of the solitary tract of spontaneously hypertensive and Wistar-Kyoto normotensive rats in response to drug-induced changes in arterial blood pressure. Brain Res Bull 40: 111-116.
33. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, Tassin JP. 2002. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22: 2873-2884.
34. Fadel J, Deutch AY. 2002. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience 111: 379-387.
35. Fallon JH, Loughlin SE. 1982. Monoamine innervation of the forebrain: collateralization. Brain Res Bull 9: 295-307.
36. Filipek PA, SemruD-Clikeman M, Steingard RJ, Renshaw PF, Kennedy DN, Blederman J. 1997. Volumetric MRI analysis comparing attention-deficit hyperactivity disorder and normal controls. Neurology 48: 589-601.
37. Foote SL, Bloom FE, Aston-Jones G. 1983. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63: 844-914.
38. Foote SL, Morrison JH. 1987. Extrathalamic modulation of cortical function. Annu Rev Neurosci 10: 67-95.
39. Fuster JM. 2000. Executive frontal functions. Exp Brain Res 133: 66-70.
40. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M. 1998. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95: 9991-9996.
41. Goldman-Rakic PS. 1996. Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 93: 13473-13480.
42. Gradin KA, Li JY, Andersson O, Simonsen U. 2003. Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric small arteries from spontaneously hypertensive rats. J Vasc Res 40: 252-265.
43. Grimsby J, Toth M, Chen K, Kumazawa T, Klaidman L, Adams JD, et al. 1997. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 17: 206-210.
44. Gritti I, Mainville L, Mancia M, Jones BE. 1997. GABAergic and other noncholinergic basal forebrain neurons, together with cholinergic neurons, project to the mesocortex and isocortex in the rat. J Comp Neurol 383: 163-177.
45. Hellstrand K, Engel J. 1980. Locomotor activity and catecholamine receptor binding in adult normotensive and spontaneously hypertensive rats. J Neural Transm 48: 57-63.
46. Hirsch MR, Tiveron MC, Guillemot F, Brunet JF, Goridis C. 1998. Control of noradrenergic differentiation and Phox2a expression by MASHI in the central and peripheral nervous system. Development 125: 599-608.
47. Howes LG, Rowe PR, Summers RJ, Louis WJ.1984. Age related changes of catecholamines and their metabolites in central nervous system regions of spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. Clin Exp Hypertens A 6: 2263-2277.
48. Hunt RD, Arnsten AF, Asbell MD. 1995. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34: 50-54.
49. Hynd GW, SemruD-Clikeman M, Lorys A, Novey ES, Eliopulos D. 1990. Brain morphology in developmental dyslexia and attention deficit disorder/hyperactivity. Arch Neurol 47: 919-928.
50. Ihalainen JA, Tanila H, Scheinin M, Riekkinen P, Jr. 2001. alpha(2C)-Adrenoceptors modulate the effect of methylphenidate on response rate and discrimination accuracy in an operant test. Brain Res Bull 54: 553-557.
51. Jimenez-Altayo F, Giraldo J, McGrath JC, Vila E. Enhanced noradrenergic transmission in the spontaneously hypertensive rat anococcygeus muscle. Br J Pharmacol 2003. 140: 773-779.
52. Jodo E, Chiang C, Aston-Jones G. 1998. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 83: 63-79.
53. Kaehler ST, Sinner C, Philippu A. 2000. Release of catecholamines in the locus coeruleus of freely moving and anaesthetized normotensive and spontaneously hypertensive rats: effects of cardiovascular changes and tail pinch. Naunyn Schmiedebergs Arch Pharmacol 361: 433-439.
54. Kalivas PW, Churchill L, Klitenick MA. 1993. The circuitry mediating the translation of motivational stimuli into adaptive motor responses. In: Kalivas PW, Barnes CD, ed, Limbic motor circuits and Neuropsychiatry. Boca Raton, Florida, USA: CRC Press; 237-275.
55. Kawahara H, Kawahara Y, Westerink BH. 2001. The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis. Eur J Pharmacol 418: 177-186.
56. King JA, Barkley RA, Delville Y, Ferris CF. 2000. Early androgen treatment decreases cognitive function and catecholamine innervation in an animal model of ADHD. Behav Brain Res 107: 35-43.
57. Kobayashi K, Morita S, Mizuguchi T, Sawada H, Yamada K, Nagatsu I, et al. 1994. Functional and high level expression of human dopamine beta-hydroxylase in transgenic mice. J Biol Chem 269: 29725-29731.
58. Kobayashi K, Morita S, Sawada H, Mizuguchi T, Yamada K, Nagatsu I, et al. 1995. Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J Biol Chem 270: 27235-27243.
59. Kobayashi K, Noda Y, Matsushita N, Nishii K, Sawada H, Nagatsu T, et al. 2000. Modest neuro-psychological deficits caused by reduced nor-adrenaline metabolism in mice heterozygous for a mutated tyrosine hydroxylase gate. J Neurosci 20: 2418-2426.
60. Kuczenski R, Segal DS 2001. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296: 876-883.
61. Kuczenski R, Segal DS, Cho AK, Melega W. 1995. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15: 1308-1317.
62. Kumai T, Oonuma S, Kitaoka Y, Tadokoro M, Kobayashi S. 2003. Biochemical and morphological characterization of spontaneously hypertensive hyperlipidaemic rats. Clin Exp Pharmacol Physiol 30: 537-544.
63. Kumai T, Tanaka M, Watanabe M, Nakura H, Tateishi T, Kobayashi S. 1996. Elevated tyrosine hydroxylase mRNA levels in medulla oblongata of spontaneously hypertensive rats. Brain Res Mol Brain Res 36: 197-199.
64. Lacroix D, Ferron A. 1988. Electrophysiological effects of methylphenidate on the coeruleo-cortical noradrenergic system in the rat. Eur J Pharmacol 149: 277-285.
65. Lahdesmaki J, Sallinen J, MacDonald E, Kobilka BK, Fagerholm V, Scheinin M. 2002. Behavioral and neurochemical characterization of alpha(2A)-adrenergic receptor knockout mice. Neuroscience 113: 289-299.
66. Langleben DD, Austin G, Krikorian G, Ridlehuber HW, Goris ML, Strauss HW. 2001. Interhemispheric asymmetry of regional cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. Nucl Med Commun 22: 1333-1340.
67. Lee A, Wissekerke AE, Rosin DL, Lynch KR. 1998. Localization of alpha2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience 84: 1085-1096.
68. Leo D, Sorrentino E, Volpicelli F, Eyman M, Greco D, Viggiano D, et al. 2003. Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 27: 661-669.
69. Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH. 2001. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 297: 540-546.
70. Loughlin SE, Foote SL, Fallon JH. 1982. Locus coeruleus projections to cortex: topography, morphology and collateralization. Brain Res Bull 9: 287-294.
71. Mason ST. 1981. Noradrenaline in the brain: Progress in theories of behavioral function. Prog Neurobiol 16: 263-303.
72. McAlonan K, Brown VJ. 2003. Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res 146: 97-103.
73. Monda M, Viggiano A, Viggiano A, Fuccio F, De L,V. 2004. Cortical spreading depression blocks the hyperthermic reaction induced by orexin a. Neuroscience 123: 567-574.
74. Morin X, Cremer H, Hirsch MR, Kapur RP, Goridis C, et al. 1997. Defects in sensory and autonomic ganglia and absence of locus coeruleus in mice deficient for the homeobox gene Phox2a. Neuron 18: 411-423.
75. Mostofsky SH, Cooper KL, Kates WR, Denckla MB, Kaufmann WE. 2002. Smaller prefrontal and pre-motor volumes in boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 52: 785-794.
76. Mulder AB, Nordquist RE, Orgut O, Pennartz CM. 2003. Learning-related changes in response patterns of prefrontal neurons during instrumental conditioning. Behav Brain Res 146: 77-88.
77. Murugaiah KD, O'Donnell JM. 1995. Beta adrenergic receptors facilitate norepinephrine release from rat hypothalamic and hippocampal slices. Res Commun Mol Pathol Pharmacol 90: 179-190.
78. Naga Prasad SV, Nienaber J, Rockman HA. 2001. Beta-adrenergic axis and heart disease. Trends Genet 17: S44-S49.
79. Newman DB, Hilleary SK, Ginsberg CY. 1989. Nuclear terminations of corticoreticular fiber systems in rats. Brain Behav Evol 34: 223-264.
80. O'Donnell JM. 1993. Effect of the beta-2 adrenergic agonist zinterol on norepinephrine turnover. Res Commun Chem Pathol Pharmacol 80: 113-116.
81. Olpe HR, Berecek K, Jones RS, Steinmann MW, Sonnenburg C, Hofbauer KG. 1985. Reduced activity of locus coeruleus neurons in hypertensive rats. Neurosci Lett 61: 25-29.
82. Oostendorp J, Preitner F, Moffatt J, Jimenez M, Giacobino JP, Molenaar P, et al.. 2000. Contribution of beta-adrenoceptor subtypes to relaxation of colon and oesophagus and pacemaker activity of ureter in wildtype and beta(3)-adrenoceptor knockout mice. Br J Pharmacol 130: 747-758.
83. Phillipson OT. 1979. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J Comp Neurol 187: 117-143.
84. Pueyo R, Maneru C, Vendrell P, Mataro M, Estevez-Gonzalez A, Garcia-Sanchez C, et al. 2000. [Attention deficit hyperactivity disorder. Cerebral asymmetry observed on magnetic resonance]. Rev Neurol 30: 920-925.
85. Raskin LA, Shaywitz BA, Anderson GM, Cohen DJ, Teicher MH, Linakis J. 1983. Differential effects of selective dopamine, norepinephrine or cate-cholamine depletion on activity and learning in the developing rat. Pharmacol Biochem Behav 19: 743-749.
86. Reith ME, Li MY, Yan QS. 1997. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl) 134: 309-317.
87. Reja V, Goodchild AK, Phillips JK, Pilowsky PM. 2002. Tyrosine hydroxylase gene expression in ventrolateral medulla oblongata of WKY and SHR: a quantitative real-time polymerase chain reaction study. Auton Neurosci 98: 79-84.
88. Robbins TW. 1997. Arousal systems and attentional processes. Biol Psychol 45: 57-71.
89. Rubia K, Overmeyer S, Taylor E, Brammer M, Williams SC, Simmons A, et al. 2000. Functional frontalisation with age: mapping neurodevelopmental trajectories with fMRI. Neurosci Biobehav Rev 24: 13-19.
90. Russell V, Allie S, Wiggins T. 2000. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res 117: 69-74.
91. Sadile AG. 1996. Long-term habituation of theta-related activity components of albino rats in the Làt-maze. In: Sanberg PR, Ossenkopp KP, Kavaliers M, eds, Motor Activity and Movement Disorders: Measurement and Analysis. New York, NY, USA: Humana Press; 1-54.
92. Sallinen J, Haapalinna A, MacDonald E, Viitamaa T, Lahdesmaki J, Rybnikova E, et al. 1999. Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol Psychiatry 4: 443-452.
93. Schramm NL, McDonald MP, Limbird LE. 2001. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci 21: 4875-4882.
94. Sergeant JA, Geurts H, Huijbregts S, Scheres A, Oosterlaan J. 2003. The top and the bottom of ADHD: a neuropsychological perspective. Neurosci Biobehav Rev 27: 583-592.
95. Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS. 2000. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci 20: 3504-3511.
96. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. 1998. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyper-activity disorder. Am J Psychiatry 155: 693-695.
97. Spreng M, Cotecchia S, Schenk F. 2001. A behavioral study of Alpha-1B adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities. Neurobiol Learn Mem 75: 214-229.
98. Swanson LW. 1982. The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9: 321-353.
99. Szot P, Weinshenker D, White SS, Robbins CA, Rust NC, Schwartzkroin PA, et al. 1999. Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J Neurosci 19: 10985-10992.
100. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, et al. 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94: 9938-9943.
101. Tanaka J, Miyakubo H, Hayashi Y. 2002. Decreased monoamine release in the median preoptic area following ventricular treatment with the angiotensin 11 antagonist saralasin in normotensive and spontaneously hypertensive rats. Regul Pept 107: 71-77.
102. Tanoue A, Koshimizu TA, Tsujimoto G. 2002. Transgenic studies of alpha(1)-adrenergic receptor subtype function. Life Sci 71: 2207-2215.
103. Thomas DN, Holman RB. 1991. A microdialysis study of the regulation of endogenous noradrenaline release in the rat hippocampus. J Neurochem 56: 1741-1746.
104. Thomas SA, Marck BT, Palmiter RD, Matsumoto AM. 1998. Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase. J Neurochem 70: 2468-2476.
105. Thomas SA, Palmiter RD. 1997. Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. Behav Neurosci 111: 579-589.
106. Torrealba F, Yanagisawa M, Saper CB. 2003. Colocalization of orexin a and glutamate immuno-reactivity in axon terminals in the tuberomammillary nucleus in rats. Neuroscience 119: 1033-1044.
107. Uylings HB, Groenewegen HJ, Kolb B. 2003. Do rats have a prefrontal cortex? Behav Brain Res 146: 3-17.
108. Vafaei AA, Rashidy-Pour A. 2004. Reversible lesion of the rat's orbitofrontal cortex interferes with hippocampus-dependent spatial memory. Behav Brain Res 149: 61-68.
109. Vanderschuren LJ, Wardeh G, De Vries TJ, Mulder AH, Schoffelmeer AN. 1999. Opposing role of dopamine D1 and D2 receptors in modulation of rat nucleus accumbens noradrenaline release. J Neurosci 19: 4123-4131.
110. Viggiano D, Grammatikopoulos G, Sadile AG. 2002. A morphometric evidence for a hyperfunctioning mesolimbic system in an animal model of ADHD. Behav Brain Res 130: 181-189.
111. Viggiano D, Ruocco LA, Pignatelli M, Grammatikopoulos G, Sadile AG. 2003. Prenatal elevation of endocannabinois corrects the unbalance between dopamine systems and reduces activity in the Naples High Excitability rats. Neurosci Biobehav Rev 27: 129-139.
112. Viggiano D, Sadile AG. 2000. Hypertrophic A10 dopamine neurons in a rat model of Attention-deficit Hyperactivity Disorder (ADHD). Neuroreport 11: 3677-3680.
113. Viggiano D, Vallone D, Ruocco LA, Sadile AG. 2003. Behavioural, pharmacological, morpho-functional molecular studies reveal a hyperfunctioning mesocortical dopamine system in an animal model of attention deficit and hyperactivity disorder. Neurosci Biobehav Rev 27: 683-689.
114. Viggiano D, Vallone D, Sadile AG. 2004. Dysfunctions in the dopamine systems and ADHD: evidences from animals and modeling. Neural Plast 11: 93-116.
115. Viggiano D, Vallone D, Welzl H, Sadile AG. 2002. The Naples high- and low excitability rats: selective breeding, behavioral profile, morphometry and molecular biology of the mesocortical dopamine system. Behav Genet 32: 315-333.
116. Weinshenker D, Miller NS, Blizinsky K, Laughlin ML, Palmiter RD. 2002. Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. Proc Natl Acad Sci USA 99: 13873-13877.
117. Williams J, Taylor E. 2004. Dopamine appetite and cognitive impairment in Attention Deficit/Hyperactivity Disorder. Neural Plast 2004. 11: 117-134.
118. Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, et al. 2000. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818-829.
119. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, et al. 2000. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3: 465-471.
120. Yavich L, Lappalainen R, Sirvio J, Haapalinna, A, MacDonald E. 1997. Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur J Pharmacol 339: 113-119.
121. Zhou QY, Palmiter RD. 1995. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83: 1197-1209.
122. Zhou QY, Quaife CJ, Palmiter RD. 1995. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374: 640-643.
123. Zuscik MJ, Sands S, Ross SA, Waugh DJ, Gaivin RJ, Morilak D, et al. 2000. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat Med 6: 1388-1394.
124. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. 2001. Impaired activity of the extra-neuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3 -deficient mice. Mol Cell Biol 21: 4188-4196.